AstraZeneca's prostate cancer drug meets primary goal

Writer,

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Drug maker AstraZeneca said its prostate cancer drug in combination with abiraterone developed with MSD, had met the primary goal of a phase 3 trial trial.

The Independent Data Monitoring Committee concluded that the trial met the primary endpoint of radiographic progression-free survival in men with metastatic castration-resistant prostate cancer who had not received treatment in the 1st-line setting including with new hormonal agents or chemotherapy.

The trial also showed a trend at this interim analysis towards improved overall survival, but the data are 'still immature and the trial will continue to assess overall survival as a key secondary endpoint,' the company said.